Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

331 ARTÍCULOS , VIENDO DEL 301 AL 315

β-Amyloid peptides display protective activity against the human Alzheimer's disease-associated herpes simplex virus-1

Bourgade K, Garneau H, Giroux G, Le Page AY, Bocti C, Dupuis G, Frost EH, Fülöp T Jr.

Biogerontology. 2015 Feb;16(1):85-98. doi: 10.1007/s10522-014-9538-8. Epub 2014 Nov 7.

How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story

Richardson A, Galvan V, Lin AL, Oddo S.

Exp Gerontol. 2015 Aug;68:51-8. doi: 10.1016/j.exger.2014.12.002. Epub 2014 Dec 3.

Seizures in Alzheimer's disease

Born HA.

Neuroscience. 2015 Feb 12;286:251-63. doi: 10.1016/j.neuroscience.2014.11.051. Epub 2014 Dec 4.

A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD)

Ballard C, Thomas A, Gerry S, Yu LM, Aarsland D, Merritt C, Corbett A, Davison C, Sharma N, Khan Z, Creese B, Loughlin P, Bannister C, Burns A, Win SN, Walker Z; MAIN-AD investigators.

J Am Med Dir Assoc. 2015 Apr;16(4):316-22. doi: 10.1016/j.jamda.2014.11.002. Epub 2014 Dec 15.

Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study

Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, Abner EL, Petersen RC, Federoff HJ, Miller BL, Goetzl EJ.

Alzheimers Dement. 2015 Jun;11(6):600-7.e1. doi: 10.1016/j.jalz.2014.06.008. Epub 2014 Aug 15.

Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials

Donohue MC, Moghadam SH, Roe AD, Sun CK, Edland SD, Thomas RG, Petersen RC, Sano M, Galasko D, Aisen PS, Rissman RA.

Alzheimers Dement. 2015 Sep;11(9):1069-79. doi: 10.1016/j.jalz.2014.07.156. Epub 2014 Oct 7.

Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease

Schaffer C, Sarad N, DeCrumpe A, Goswami D, Herrmann S, Morales J, Patel P, Osborne J.

J Lab Autom. 2015 Oct;20(5):589-600. doi: 10.1177/2211068214559979. Epub 2014 Nov 25.

Targeting microglia for the treatment of Alzheimer's disease

McGeer PL, McGeer EG.

Expert Opin Ther Targets. 2015 Apr;19(4):497-506. doi: 10.1517/14728222.2014.988707. Epub 2014 Nov 29.

Cognitive intervention therapy as treatment for behaviour disorders in Alzheimer disease: evidence on efficacy and neurobiological correlations

García-Alberca JM.

Neurologia. 2015 Jan-Feb;30(1):8-15. doi: 10.1016/j.nrl.2012.10.002. Epub 2012 Dec 15.

The use of pharmacological retromer chaperones in Alzheimer's disease and other endosomal-related disorders

Berman DE, Ringe D, Petsko GA, Small SA.

Neurotherapeutics. 2015 Jan;12(1):12-8. doi: 10.1007/s13311-014-0321-y.

Oxidative stress and neurodegenerative diseases: looking for a therapeutic solution inspired on benzopyran chemistry

Gaspar A, Milhazes N, Santana L, Uriarte E, Borges F, Matos MJ.

Curr Top Med Chem. 2015;15(5):432-45.

Retromer in Alzheimer disease, Parkinson disease and other neurological disorders

Small SA, Petsko GA.

Nat Rev Neurosci. 2015 Mar;16(3):126-32. doi: 10.1038/nrn3896. Epub 2015 Feb 11.

Compromised MAPK signaling in human diseases: an update

Kim EK, Choi EJ.

Arch Toxicol. 2015 Jun;89(6):867-82. doi: 10.1007/s00204-015-1472-2. Epub 2015 Feb 18.

Is lithium a neuroprotective agent?

Vo TM, Perry P, Ellerby M, Bohnert K.

Ann Clin Psychiatry. 2015 Feb;27(1):49-54.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias